Advertisement

Journal of Pharmacokinetics and Biopharmaceutics

, Volume 6, Issue 6, pp 539–546 | Cite as

Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve

  • Win L. Chiou
Article

Abstract

The linear trapezoidal rule method is commonly used for the estimation of the area under the plasma level-time curve. Error analyses are performed when the method is used in first-order absorption and first-order elimination kinetics in the one-compartment system. It is found that significant underestimations and overestimations in area during the absorption phase and postabsorption phase, respectively, can occur when the method is improperly used. During the exponential postabsorption phase the relative error is only a function of the ratio (n)of the time interval over the half-life of the two plasma data points in the interval. The error from the linear trapezoidal rule method at n=0.5 is about 1%. The error increases to 15.5% and 57.1 % when nis increased to 2 and 4, respectively. It is recommended that for most absorption studies the linear trapezoidal method be used for prepeak and plateau plasma data and the logarithmic trapezoidal method for postpeak plasma data.

Key words

trapezoidal rule area under the curve pharmacokinetics clearance bioavailability integration method sulfisoxazole 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    S. A. Kaplan. Biopharmaceutics in the pre-formulation stages of drug development. In J. Swarbrick (ed.),Current Concepts in the Pharmaceutical Sciences: Dosage Form Design and Bioavailability, Lea and Febiger, Philadelphia, 1973, Chap. 1.Google Scholar
  2. 2.
    M. Gibaldi and D. Perrier.Pharmacokinetics, Dekker, 1975, pp. 67, 132, and 293.Google Scholar
  3. 3.
    D.S. Riggs.The Mathematical Approach to Physiological Problems, Williams and Wilkins, Baltimore, 1967.Google Scholar
  4. 4.
    W. L. Chiou, M. A. F. Gadalla, and G. W. Peng. Method for the rapid estimation of the total body drug clearance and adjustment of dosage regimens in patients during a constant-rate intravenous infusion.J. Pharmacokin. Biopharm. 6:135–152 (1978).CrossRefGoogle Scholar
  5. 5.
    K. C. Yeh and K. C. Kwan. A comparison of numerical integrating logarithms by trapezoidal, Lagrange, and spline approximation.J. Pharmacokin. Biopharm. 6:79–98 (1978).CrossRefGoogle Scholar
  6. 6.
    P. G. Welling, L. L. Lyons, W. A. Craig, and G. A. Trochta. Influence of diet and fluid on bioavailability of theophylline.Clin. Pharmacol. Ther. 17:475–480 (1975).PubMedGoogle Scholar
  7. 7.
    P. G. Welling, P. A. Koch, C. C. Lau, and W. A. Craig. Bioavailability of tetracycline and doscycline in fasted and nonfasted subjects.Antimicrob. Agents Chemother. 11:462–469 (1977).PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    S. A. Kaplan, R. E. Weinfeld, C. W. Abruzzo, and M. Lewis. Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man.J. Pharm. Sci. 61:773–778 (1972).PubMedCrossRefGoogle Scholar
  9. 9.
    C. T. Ueda and B. S. Dzindzio. Quinidine kinetics in congestive heart failure.Clin. Pharmacol. Ther. 23:158–164 (1978).PubMedGoogle Scholar
  10. 10.
    K. C. Kwan and A. E. Till. Novel method for bioavailability assessment.J. Pharm. Sci. 62:1494–1497 (1973).PubMedCrossRefGoogle Scholar
  11. 11.
    A. E. Till, L. Z. Benet, and K. C. Kwan. An integrated approach to the pharmacokinetic analysis of drug absorption.J. Pharmacokin. Biopharm. 2:525–544 (1974).CrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1978

Authors and Affiliations

  • Win L. Chiou
    • 1
  1. 1.Clinical Pharmacokinetics Laboratory and Department of Pharmacy, College of PharmacyUniversity of Illinois at the Medical CenterChicago

Personalised recommendations